CCCC
C4 Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▲ C4 Therapeutics reported financial results for Q4 and full year 2025…
- Feb 28 ▲ Three major institutional investors, Morgan Stanley, Wells Fargo, an…
- Apr 9 ▲ C4 Therapeutics entered a research collaboration and license agreeme…
- Apr 9 ▲ C4 Therapeutics announced a collaboration with Roche to develop degr…
- May 18 Activist stake: C4 Therapeutics Announces Inducement Grant Under Nasdaq Li…
- Jun 11 ▲ C4 Therapeutics presented updated Phase 1 data for cemsidomide at EH…
- Jun 11 FDA: C4 Therapeutics Presents Phase 1 Data at European Hematolo…
- Aug 14 ▲ Eight major institutional investors, including BlackRock, State Stre…
- Sep 25 FDA: C4 Therapeutics Presents New Biomarker Data from the Cemsi…
- Oct 9 JP Morgan initiates
- Oct 28 Lake Street initiates
- Nov 12 ▼ 1 insider sell $122.5K at $2.71
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $122.5K.
- InstitutionsBULLISH
Q3 2026: 28 added (0 new), 6 trimmed or exited.
- AnalystsBULLISH
14 of 15 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.268 → −$0.198 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +9.0% to 46.58M shares. 15.1 days to cover, ≈35.5% of shares.
- TrendRANGE
15% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Candriam S.C.A. | ADD | $9.2M |
| Qube Research & Technologies Ltd | DOUBLED | $8.0M |
| CONGRESS ASSET MANAGEMENT CO | ADD | $4.2M |
| FMR LLC | ADD | $3.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $3.6M |
| MARSHALL WACE, LLP | DOUBLED | $2.8M |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | $2.3M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | $1.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analystsPrice is below the lowest target. Median implies +296%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 28, 2026 | Lake Street INITIATE | Buy |
| Oct 9, 2026 | JP Morgan INITIATE | Overweight |
| Jun 1, 2026 | Evercore ISI Group MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Adams Kendra Chief Financial Officer Nov 12, 2026 | SELL | $122.5K |
Anderson Kenneth Carl Director Oct 1, 2026 | AWARD | $11.5K |
GROGAN DONNA ROY Director Oct 1, 2026 | AWARD | $14.5K |
Adams Kendra Chief Financial Officer Sep 18, 2026 | EXERCISE | 6,250 sh |
Adams Kendra Chief Financial Officer Sep 18, 2026 | TAX W/H | $9.4K |
REYNO LEONARD Chief Medical Officer Jul 10, 2026 | EXERCISE | 15,325 sh |
REYNO LEONARD Chief Medical Officer Jul 10, 2026 | TAX W/H | $30.0K |
Anderson Kenneth Carl Director Jul 1, 2026 | AWARD | $11.5K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.20 | -$0.25–-$0.15 | +27.3% | $5.9M |
| Next Q | -$0.26 | -$0.34–-$0.19 | +11.9% | $5.3M |
| Current FY | -$0.74 | -$0.80–-$0.69 | +16.4% | $26.9M |
| Next FY | -$0.87 | -$1.11–-$0.68 | +13.1% | $23.5M |
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 4 press releases · 4 bullish · 0 bearish · 1 mixed · 10 neutral- NEUTRAL SC 13G/ANov 16, 2026
Squadron Capital Management filed an amended Schedule 13G reporting a 7.9% passive stake in C4 Therapeutics as of September 30, 2026, unchanged from its prior filing. The filing confirms Squadron's continued passive position with no change in ownership or intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 12, 2026
Kendra Adams, an officer of C4 Therapeutics, filed a Form 144 notice of intent to sell 45,173…
The sale appears to be a routine disposition of vested equity awards by an officer. The dollar amount is modest relative to the company's market cap. Monitor for any subsequent Form 4 filings to…
- NEUTRAL INST-CLUSTERNov 6, 2026
Five institutional investors added to C4 Therapeutics positions in Q3 2026, with Candriam S.c.a…
The cluster is small and stale; the revenue decline and lack of insider buying limit conviction. Watch for Q4 2026 results and Phase 2 MOMENTUM trial enrollment completion in Q1 2027 as potential…
- NEUTRAL 8-KNov 5, 2026
C4 Therapeutics reported Q3 2026 revenue of $8.5M, down 24.6% YoY from $11.2M, and a net loss of…
The revenue decline is structural (end of Merck/Merck KGaA collaborations) and partially offset by the Roche DAC deal. The key catalysts are the Phase 2 MOMENTUM enrollment completion (Q1 2027) and…
All CCCC filing & press-release reports (19)
- SC 13G/A reportNov 16, 2026
- 144 reportNov 12, 2026
- INST-CLUSTER reportNov 6, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportSep 25, 2026
- PRESS-RELEASE reportSep 25, 2026
- 144 reportAug 14, 2026
- INST-CLUSTER reportAug 14, 2026
- 8-K reportAug 11, 2026
- PRESS-RELEASE reportJun 11, 2026
- 8-K reportMay 15, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 8-K reportApr 9, 2026
- PRESS-RELEASE reportApr 9, 2026
- PRESS-RELEASE reportMar 25, 2026
- INST-CLUSTER reportFeb 28, 2026
- 8-K reportFeb 26, 2026